Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 RANI | Healthcare | $0.53 | 552.87K | $73.21M | -2.78 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| RANI | Rani Therapeutics Holdings | 0.53 | -1.35 | -72.02% |
| Name | Price | % Change | |
|---|---|---|---|
| RANI | $0.53 | -72.02% |
An update from Rani Therapeutics Holdings ( ($RANI) ) is now available. Rani Therapeutics Holdings received Nasdaq approval on November 10, 2026, to transfer its Class A common-stock listing from
Edward Nash, an analyst from Canaccord Genuity, maintained the Buy rating on Rani Therapeutics Holdings. The associated price target remains the same with $5.00. Edward Nash gave his rating based
Reports Q3 revenue $1.71M, consensus $1.28M. “The third quarter marked continued progress for the RaniPill platform and, most recently, our acceptance into the FDA’s Emerging Technology Program in October provides
Rani Therapeutics (RANI) announced that the RaniPill Capsule platform technology has been accepted into the FDA Emerging Technology Program. The FDA’s Emerging Technology Program, administered within the Agency’s Center for
Chardan initiated coverage of Rani Therapeutics (RANI) with a Buy rating and $6 price target The company offers is “best-in-class” among oral delivery platforms for injectable biologics, the analyst tells
“We made significant progress in the second quarter, as we continue to expand the RaniPill oral delivery platform,” said Talat Imran, Chief Executive Officer of Rani Therapeutics (RANI). “We reported
Rani Therapeutics Holdings ( ($RANI) ) just unveiled an announcement. On August 1, 2026, Rani Therapeutics Holdings appointed Michelle Gilson to its Board of Directors and named her chair of
Insiders have been trading these 5 stocks: (($SGMT)), (($PNC)), (($URI)), (($RANI)) and (($SCCO)). Here is a breakdown of their recent trades and their value. President & CEO David Happel’s recent
Rani Therapeutics (RANI) reported initial data from the ongoing Phase 1 study of RT-114, an orally administered RaniPill Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed by ProGen. The
H.C. Wainwright analyst Brandon Folkes has maintained their bullish stance on RANI stock, giving a Buy rating on July 10. Brandon Folkes has given his Buy rating due to a
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| RANI | Mar 31, 2027TBA | $73.21M | $-0.05 | $1.60M | 0.05 | -2.78 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
